Bioreactor model for drug efficacy studies
2018
University of Florida, Orlando, USA
Nowadays, HER2+ resistant breast cancer is a major clinical challenge. Several studies have shown some of the pathways that are responsible for the acquisition of resistance of this type of tumors, which can be targeted with different already available drugs. Here, a classic 2D and a novel bioreactor-based 3D models are developed to study a triple combination therapy that targets the known pathways responsible for chemotherapy resistance in human breast cancer cells. The results show that treatment with paclitaxel, everolimus and dasatinib induced cell apoptosis in 2D conditions and in the bioreactor 3D dynamic model. With these results, a pharmacokinetics/dynamics mathematical model was generated to correlate the exposure to the novel combinational therapy and its anti-cancer effects. In this study, the researchers demonstrate the utility of a bioreactor-based 3D dynamic model to perform drug screening in an in vitro set-up that replicates in vivo conditions and demonstrate the efficacy of a novel combination therapy that can overcome HER2+ induced drug resistance.
Utility of a novel three-dimensional and dynamic (3DD) cell culture system for PK/PD studies: evaluation of a triple combination therapy at overcoming anti-HER2 treatment resistance in breast cancer
Sihem Ait-Oudhia
Added on: 10-09-2021
[1] https://www.frontiersin.org/articles/10.3389/fphar.2018.00403[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
